Cantor Fitzgerald reiterated their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report released on Thursday morning, Zacks.com reports.

Several other equities analysts also recently commented on FOLD. ValuEngine raised shares of Amicus Therapeutics from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Cowen set a $31.00 price objective on shares of Amicus Therapeutics and gave the company a buy rating in a research note on Thursday, October 10th. BidaskClub raised shares of Amicus Therapeutics from a strong sell rating to a sell rating in a research note on Friday, October 4th. Finally, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Amicus Therapeutics in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $18.93.

Shares of NASDAQ:FOLD opened at $8.13 on Thursday. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -6.11 and a beta of 1.57. The company has a 50-day moving average price of $8.85 and a 200-day moving average price of $11.41. The company has a current ratio of 7.09, a quick ratio of 6.97 and a debt-to-equity ratio of 0.31. Amicus Therapeutics has a 12 month low of $7.11 and a 12 month high of $14.61.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). The firm had revenue of $44.13 million during the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The company’s quarterly revenue was up 107.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.33) earnings per share. As a group, research analysts forecast that Amicus Therapeutics will post -1.38 EPS for the current fiscal year.

In related news, Director Burke W. Whitman purchased 4,945 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average price of $10.07 per share, for a total transaction of $49,796.15. Following the completion of the transaction, the director now directly owns 21,612 shares of the company’s stock, valued at $217,632.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $12.54, for a total transaction of $250,800.00. Following the transaction, the chief executive officer now owns 770,194 shares in the company, valued at approximately $9,658,232.76. The disclosure for this sale can be found here. Insiders have sold 54,500 shares of company stock worth $567,945 in the last quarter. 2.50% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new position in shares of Amicus Therapeutics during the second quarter valued at about $49,000. US Bancorp DE increased its position in shares of Amicus Therapeutics by 50.9% during the second quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,651 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Amicus Therapeutics during the second quarter valued at about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in shares of Amicus Therapeutics during the second quarter valued at about $122,000. Finally, Weil Company Inc. purchased a new position in shares of Amicus Therapeutics during the second quarter valued at about $125,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: Mutual Funds

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.